A carregar...

Phase II Study of Dutasteride for Recurrent Prostate Cancer During Androgen Deprivation Therapy

PURPOSE: We determined the response rate to and safety of a dual 5α-reductase inhibitor, dutasteride, in men with castration recurrent prostate cancer. MATERIALS AND METHODS: A total of 28 men with asymptomatic castration recurrent prostate cancer were treated with 3.5 mg dutasteride daily (luteiniz...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Shah, Satyan K., Trump, Donald L., Sartor, Oliver, Tan, Wei, Wilding, Gregory E., Mohler, James L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2008
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2851185/
https://ncbi.nlm.nih.gov/pubmed/19091347
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.juro.2008.10.014
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!